Revenue
Trailing-twelve-month (TTM) revenue is $2.90 Billion with a year-over-year growth of +30.75%. Revenue represents the total income generated from the company's primary business operations.
PODD Revenue
Reported quarterly revenue; no daily interpolation.
Limited quarterly history available
Revenue needs at least three reported quarters before a meaningful chart is shown.
PODD Revenue by Segment
How PODD’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2025)
- International Omnipod$2.67B98.7%
- Drug Delivery$34.10M1.3%
By geography (FY 2025)
- United States$1.95B72.2%
- Non-US$754.30M27.9%
PODD Revenue by Product / Business (history)
How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.
- International Omnipod
- Drug Delivery
PODD Revenue by Geography (history)
How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.
- United States
- Non-US
Revenue (TTM)
$2.90B
$2.90 Billion
Year-over-Year Growth
+30.75%
vs. $2.22B a year ago (TTM)
Revenue CAGR
+24.53%
5 Year compound annual growth rate
Revenue CAGR (Compound Annual Growth Rate)
1 Year
+30.75%
3 Year
+27.53%
5 Year
+24.53%
10 Year
+26.21%
15 Year
+24.85%
20 Year
+72.46%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Revenue History
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.71B | +$636.50M | +30.73% |
| 2024 | $2.07B | +$374.50M | +22.07% |
| 2023 | $1.70B | +$391.80M | +30.02% |
| 2022 | $1.31B | +$206.50M | +18.79% |
| 2021 | $1.10B | +$194.40M | +21.49% |
| 2020 | $904.40M | +$166.20M | +22.51% |
| 2019 | $738.20M | +$174.38M | +30.93% |
| 2018 | $563.82M | +$100.06M | +21.57% |
| 2017 | $463.77M | +$96.78M | +26.37% |
| 2016 | $366.99M | +$103.10M | +39.07% |
Revenue Growth Summary
TTM Growth
+30.75%
3-Year Avg Growth
+27.53%
5-Year Avg Growth
+24.53%
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy